Physician profile
Amy Ostrofe
NPI 1942569645
$5,719.99
in general payments reported to CMS, 2019-2025
14 companies · $145 in 2025
The $145 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $1,689 · 2022: $1,763 · 2023: $1,067 · 2024: $1,056 · 2025: $145.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,794 · Travel and Lodging: $474.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,794.02 |
| Travel and Lodging | $473.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fortis Surgical, LLC | $1,689.00 | 2020 | |
| Evolution Surgical, INC | $1,294.94 | 2022-2023 | |
| Arthrex, INC. | $960.66 | 2024 | |
| Axogen | $657.19 | 2022-2025 | Avance Nerve Graft |
| Trimed, INC. | $153.62 | 2023 | |
| Alafair Biosciences, INC. | $134.67 | 2023 | Versawrap |
| Elevate Surgical Co | $132.74 | 2023-2024 | |
| Stryker Corporation | $120.21 | 2022-2023 | Aequalis Perform+ |
| Bioventus LLC | $109.32 | 2023 | Exogen Ultrasound Bone Healing System |
| Integra Lifesciences Corporation | $108.86 | 2023 | Integra, Integra Dermal Regeneration Template |
| Endo Pharmaceuticals INC. | $99.40 | 2023 | Xiaflex |
| Kci USA, INC. | $95.82 | 2022 | |
| Checkpoint Surgical, INC | $93.19 | 2023 | Checkpoint Stimulators |
| Skeletal Dynamics INC | $70.37 | 2023 | Geminus, Ijs, Implate |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amy Ostrofe listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.